SPC431
Loncastuxímab tesírín á öllum formum sem eru vernduð af grunneinkaleyfinu
Status:
UmsóknApplication date:
19.5.2023Application published:
15.6.2023
Max expiry date:
21.12.2037Medicine name:
ZynlontaMedicine for children:
No
Timeline
Today
19.5.2023Application
15.6.2023Publication
21.12.2037Expires
Marketing license
IS authorization number:
EU/1/22/1695Date:
10.1.2023
Foreign authorization number:
EU/1/22/1695Date:
20.12.2022
Owner
Name:
ADC Therapeutics SAAddress:
Route de la Corniche 3B, Epalinges CH
Name:
Medimmune LimitedAddress:
Milstein Building Granta Park, Cambridge, Cambridgeshire CB21 6GH GB
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2906298